GB Sciences, Inc. (GBLX) Stock
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About GB Sciences, Inc.
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.
GB Sciences, Inc. (GBLX) stock trades at $0.00 with a market capitalization of $122121. The stock is valued at a price-to-earnings (P/E) ratio of -0.07, price-to-book of -0.02, price-to-sales of 1.26. Over the past 52 weeks the stock has ranged between $0.00 and $0.50, and currently trades 100.0% below its 52-week high.
On profitability, GB Sciences, Inc. generates a return on equity (ROE) of 20.00%, above the typical market average, an operating margin of -68.48%, a net profit margin of 0.00%.
Official website: www.gbsciences.com